Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin/Docetaxel in First-Line Metastatic Breast Cancer
NCT00193024Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2001
- Primary completion
- Oct 2003
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and epirubicin in breast cancer, sponsored by SCRI Development Innovations. Primary endpoint: Clinical response rate. Started Sep 2001; status: terminated.
02
Drugs
docetaxelepirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00193024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193024.